RecruitingACTRN12614000662662

Comparison of Contrast Enhanced UltraSound to Magnetic Resonance Imaging for the detection of synovitis in patients with haemophilic arthropathy. A pilot study


Sponsor

Dr Anne Powell

Enrollment

40 participants

Start Date

Sep 23, 2013

Study Type

Interventional

Conditions

Summary

The aim of this project is to demonstrate that contrast enhanced ultrasound is an equally effective method for detecting synovitis in patients with haemophilia in whom the diagnosis of synovitis (joint capsule inflammation) from physical examination is unclear. Currently, MRI is the screening tool for synovitis in this population; however it is time consuming, claustrophobic for some patients and has long waiting times. Contrast-enhanced ultrasound is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents may be used during an ultrasound examination to improve the clarity and accuracy of a conventional ultrasound image.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 70 Yearss

Inclusion Criteria1

  • Adult patients with haemophiliac arthropathy

Exclusion Criteria1

  • Pregnancy or breast feeding, right to left cardiovascular shunts, pulmonary hypertension, renal impairment, unstable cardiac disease, hypersensitivity to contrast agents

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Contrast enhanced ultrasound, a non ionising diagnostic imaging study using intravenously administered microbubble contrast ("Definity"). This study is performed on each participant on a single occasi

Contrast enhanced ultrasound, a non ionising diagnostic imaging study using intravenously administered microbubble contrast ("Definity"). This study is performed on each participant on a single occasion for the affected joint, and takes approximately 30-45 minutes.


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614000662662


Related Trials